Heidelberg Pharma AG Logo

Heidelberg Pharma AG

Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.

HPHA | F

Overview

Corporate Details

ISIN(s):
DE000A11QVV0
LEI:
391200E09XYBYITR1W32
Country:
Germany
Address:
Gregor-Mendel-Str. 22, 68526 Ladenburg

Description

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-03-31 07:08
Heidelberg Pharma AG: European Patent Office Grants Patent for Amatoxin Conjuga…
English 10.7 KB
2020-03-27 07:20
Heidelberg Pharma Publishes Article on Chemical Amanitin Synthesis in Angewandt…
English 11.3 KB
2020-03-19 07:04
Heidelberg Pharma Announces Financial Figures for Fiscal Year 2019 and Provides…
English 34.4 KB
2020-03-19 00:00
Annual financial report 2018/2019
German 3.1 MB
2020-03-04 14:27 English 5.5 KB
2020-03-04 07:19
Heidelberg Pharma AG: US patent rights granted for diagnosis and treatment of p…
English 10.7 KB
2020-03-04 00:00
Datum:04.03.2020
German 11.1 KB
2020-02-24 15:34
Heidelberg Pharma AG: Partner Magenta Therapeutics Presents Preclinical Data on…
English 11.5 KB
2020-01-22 09:49
Heidelberg Pharma AG Secures Financing Commitment from Its Main Shareholder die…
English 8.6 KB
2019-12-06 10:20
DGAP-DD: Heidelberg Pharma AG english
English 7.6 KB
2019-12-02 15:10
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.3 KB
2019-11-20 15:21
Heidelberg Pharma Participates in Franco-German Joint Venture Emergence Therape…
English 11.1 KB
2019-11-11 14:46
Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option to Further …
English 10.2 KB
2019-11-06 10:41
Heidelberg Pharma AG: Heidelberg Pharma Announces Participation at Various Conf…
English 11.8 KB
2019-10-25 12:30
Heidelberg Pharma AG: Notice to Holders
English 6.7 KB

Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Heidelberg Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-31 Pahl, Prof. Dr. Andreas Board Other None N/A
2023-12-18 Pahl, Prof. Dr. Andreas Board Buy None 10,130.00 EUR
2022-10-13 4H invest GmbH Close relation Other None 993,666.24 EUR
2022-10-13 Bohlini invest GmbH Close relation Other None 964,061.56 EUR
2022-10-13 MH-LT-Investments GmbH Close relation Other None 506,241.96 EUR
2022-10-13 Schneiders, Michael Board Buy None 13,088.40 EUR
2022-10-13 Schneiders, Michael Board Buy None 4,895.60 EUR
2022-09-07 Plate, Achim Board Buy None 30,869.92 EUR
2022-09-06 Kudlek, Dr. Birgit Supervisory board Other None 7,496.16 EUR
2022-03-22 4H invest GmbH Close relation Other None N/A

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.